Conclusions: Our data suggest that higher levels of PD1- and CD28-positive Exo in sera of melanoma patients before undergoing IPI treatment may predict the anti-melanoma immune activation induced by IPI and that the measurement of these molecular biomarkers could early identify the melanoma patients responsive to immunotherapy. This evidence concerns the gene CD28 and melanoma.